CMS Physician Compare site now includes star ratings, patient experience data

New data has been added to the CMS Physician Compare website, allowing the public to see star ratings based on Physician Quality Reporting System (PQRS) scores and practice information for patient satisfaction scores.

The five-star rating is scored based on “a small subset of group-level measures” in PQRS involving preventive care, care planning, diabetes, behavioral health, patient safety and heart disease.

Similar CMS star ratings have been criticized by industry groups. The American Hospital Association has repeatedly asked the agency to suspend them on the Hospital Compare site, arguing they’re “inaccurate and misleading.”

Patient satisfaction scores collected as part of the Consumer Assessment of Healthcare Providers and Systems (CAHPS) for PQRS measures for only groups will not be displayed in star ratings, but as a percentage of patients who selected the most positive responses on the surveys, which CMS said will “ensure patient experience data is interpreted correctly.”

The site will also include new data for clinicians participating in accountable care organizations (ACOs).

“2016 data for the Shared Savings Program, Pioneer, and Next Generation Accountable Care Organizations (ACOs) are now also publicly reported on Physician Compare,” CMS said. “ACO measures are reported as percent performance rates. CAHPS for ACO summary survey measures are reported as means. In this way, the CAHPS for ACO performance scores are the average of all responses available for each summary survey measure.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.